SCHEMBL10077684

SCHEMBL10077684

Cc1ccc(C(=O)Nc2ccc(F)c(Cl)c2)cc1NC(=O)/C=C/c1cccnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.58
NAMPT P43490 12/20 0.54
LMNA P02545 3/20 0.52
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
MAPT P10636 2/20 0.52
HDAC1 Q13547 1/20 0.52
GALR2 O43603 1/20 0.52
HPGD P15428 1/20 0.52
RECQL P46063 1/20 0.52
NPC1 O15118 1/20 0.50
ABL1 P00519 1/20 0.49
BCR P11274 1/20 0.49
CSF1R P07333 2/20 0.49
TP53 P04637 1/20 0.48
HTT P42858 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2678902 1.00 L3MBTL1 (0.58) L3MBTL1NAMPTLMNAKMT2AMEN1
SCHEMBL2679216 0.92 NAMPT (0.57) NAMPTLMNAKMT2AMEN1MAPT
SCHEMBL10078412 0.92 NAMPT (0.57) NAMPTLMNAKMT2AMEN1MAPT
SCHEMBL2680476 0.91 NAMPT (0.63) NAMPTLMNAKMT2AMEN1MAPT
SCHEMBL10078409 0.91 NAMPT (0.63) NAMPTLMNAKMT2AMEN1MAPT
SCHEMBL10054905 0.90 MEN1 (0.59) L3MBTL1NAMPTLMNAKMT2AMEN1
SCHEMBL2679909 0.90 MEN1 (0.59) L3MBTL1NAMPTLMNAKMT2AMEN1
SCHEMBL2678790 0.90 LCK (0.48) L3MBTL1KMT2AMEN1MAPTHDAC1
SCHEMBL10077760 0.90 LCK (0.48) L3MBTL1KMT2AMEN1MAPTHDAC1
SCHEMBL2679908 0.90 MEN1 (0.59) L3MBTL1NAMPTLMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR L3MBTL1 3034/4885NAMPT 3700/4885LMNA 4558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.